EVERSANA™ appoints experienced life science industry leaders to executive management team

News provided by

Feb 26, 2019, 09:00 ET

CHICAGO, Feb. 26, 2019 /PRNewswire/ -- EVERSANA™, the leading independent provider of global services to the life science industry, today announced three appointments to the executive leadership team. Greg Skalicky, Chief Revenue Officer, Tim Guttman, Chief Financial Officer, and Mark MacNaughton, Chief Information Officer, bring a combined 80 years of life science expertise to EVERSANA, bolstering its position as the premiere life science service provider and employer of choice.

"Last year we acquired and effectively integrated an unmatched platform of commercial services to accelerate the industry's shift to patient-centered, value-based care. Today we strengthen our leadership team with unmatched experts in the commercial, financial and technology sectors. It's a great day for the company and our clients," said Jim Lang, CEO, EVERSANA.

Greg Skalicky, Chief Revenue Officer, has worked in the pharmaceutical industry since 1995 to include executive leadership roles spanning clinical operations and business development. Previously as Chief Commercial Officer, Chief Enterprise Business Officer, EVP & General Manager at Inventiv Health, he successfully managed business units and teams of several thousand employees. Skalicky is an active member across several industry panels and consortiums.

"Life science is transforming by the minute. Our clients, especially in the areas of rare disease, oncology and regenerative medicine, demand innovative approaches to access, affordability and adherence challenges. That's why EVERSANA is leading a transformation in the service industry and finally offers a truly intregated solution to drug pricing, access, reimbursement, adherence, and product delivery," shared Skalicky.

Tim Guttman, a highly regarded financial leader in the life science industry, will serve as EVERSANA's Chief Financial Officer (CFO) effective immediately. Guttman joins EVERSANA from AmerisourceBergen, where he spent seven years as their CFO. He is widely regarded for financial excellence in pharmaceutical distribution, including specialty products, as well as the commercialization services to support these products in the market. Guttman will lead the platform's aggressive investment and growth strategies.

"EVERSANA's accelerated growth won't slow down. We'll be adding complementary capabilities to our commercial services portfolio in the coming months and years to come. Our financial outlook is strong and our team is committed to creating value in an evolving market," added Guttman.

Mark MacNaughton, who has more than thirty years of experience in information technology (IT) leadership, will serve as Chief Information Officer. With previous IT leadership roles at Cardinal Health, and Accenture, as well as being the co-founder of The Forsythe Group, MacNaughton will lead the platform's technology operation, including its global application development, IT infrastructure, security, compliance, and data and analytics.

"Advances in technology have changed this industry and will continue to do so. EVERSANA is building, acquiring and enhancing the infrastructure, data warehousing and analytics capabilities that will propel our clients' success. Technology is transforming the lives of our patients, and we will stay ahead of the curve," shared MacNaughton.

For more information on EVERSANA, visit eversana.com.

About EVERSANA™

EVERSANA™ is the leading independent provider of global services to the life science industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product lifecycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies to advance life science solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.

SOURCE EVERSANA